Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.

Analyst Commentary

Bullish and bearish analysts have provided a range of perspectives in response to recent developments at Argenx. Their commentary reflects divergent views on the company's near-term and long-term prospects, with a focus on valuation, execution, and growth opportunities.

• Bullish analysts have raised price targets significantly, citing robust quarterly results and the company's strategic focus on high-probability pipeline opportunities.
• Growth potential for Vyvgart continues to be a prime driver of optimism, with strong revenue models influenced by ongoing label expansions and geographic reach in generalized myasthenia gravis.
• Recent positive data in seronegative myasthenia gravis, coupled with multiple upcoming Phase 3 readouts for efgartimod, are seen as important catalysts for future valuation gains.
• The pipeline beyond Vyvgart, including additional indications for empasiprubart and other programs, is viewed as an underappreciated source of potential upside. This supports continued upward revisions to price targets.

• Bearish analysts have taken a more disciplined approach to valuation after a rapid increase in share price. They cite concerns about sustainability and aim to align expectations with recent market performance.
• Some caution that while top-line growth has been strong, a significant portion of future gains is already reflected in current valuations. This raises concerns about limited near-term upside.
• Skepticism remains regarding the execution risks associated with further label expansions and the competitive landscape, particularly as Argenx advances its broader pipeline.

What's in the News

• New data from pivotal Phase 3 and additional studies of VYVGART were presented at major neuromuscular medicine meetings. These findings highlight efficacy and safety across diverse generalized myasthenia gravis (gMG) patient populations (Key Developments).
• The ADAPT SERON trial demonstrated that VYVGART led to significant improvements in daily functioning for AChR-Ab seronegative gMG patients, with notable reductions in steroid use and no new safety concerns reported (Key Developments).
• argenx SE, in collaboration with FUJIFILM Biotechnologies, expanded its global manufacturing partnership to supply drug substance for efgartigimod at a new facility in North Carolina. This expansion boosts supply chain agility for clinical and commercial needs (Key Developments).
• A Special/Extraordinary Shareholders Meeting for argenx SE is scheduled for November 18, 2025, in Amsterdam, Netherlands (Key Developments).

Valuation Changes

• Consensus Analyst Price Target (Fair Value) has risen from €724.38 to €749.22. This reflects increased optimism regarding future performance.
• Discount Rate has moved up slightly from 5.26% to 5.38%. This indicates a modest upward adjustment to risk assumptions.
• Revenue Growth estimates have decreased noticeably from 31.65% to 28.05%. This highlights tempered expectations for the pace of topline expansion.
• Net Profit Margin projections have improved from 37.41% to 39.00%. This suggests analysts now anticipate greater operational efficiency.
• Future P/E ratio forecast has increased from 20.29x to 21.78x. This points to a higher valuation multiple being assigned to forward earnings.